Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection (NCT04727788)
Validation of Genomic Immune-phenotyping Profiles in Peripheral Blood Gene Signatures to Predict Risk of Kidney Transplant Rejection
🩺 Plain-English Summary (8th-Grade Level)
Global, non-randomized, observational study for the validation of Verici Dx genomic tests to predict risk of kidney clinical and subclinical acute rejection, and chronic allograft damage or interstitial fibrosis / tubular atrophy by correlating peripheral blood gene expression profiles with graft injury (e.g. cellular / antibody-mediated), rejection and death censored graft loss.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (5 items).
Location: University of Illinois at Chicago — Chicago, Illinois
Age range: 18 Years to 80 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Recipients of multiple organ transplant, except kidney-pancreas multiple transplant
- Subjects who are currently participating in a therapeutic clinical trial for transplant rejection
- HIV or Hepatitis C positive patients
- Persons who are known to be pregnant
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (13 Sites)
- University of Illinois at Chicago — Chicago, Illinois
- Northwestern University — Evanston, Illinois
- University of Maryland — Baltimore, Maryland
- Henry Ford — Detroit, Michigan
- University of Nebraska Medical Center — Omaha, Nebraska
- Cleveland Clinic — Cleveland, Ohio
- University of Pittsburgh — Pittsburgh, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- University of Washington — Seattle, Washington
- CHU Grenoble Alpes Health Center — Grenoble,
- Bologna University — Bologna,
- Brescia University — Brescia,
- University Hospital Vall d'Hebron, Barcelona — Barcelona,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant Rejection
- Microbiome and Immunosuppression: The Mission Study — Minneapolis, Minnesota
- Trifecta-Kidney cfDNA-MMDx Study — Tampa, Florida
- The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) — Birmingham, Alabama
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel — Birmingham, Alabama
- Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring — Los Angeles, California
Explore by condition: All Kidney Transplant Rejection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.